{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 45,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "Includes revenue breakdown for Ultomiris, Soliris, Strensiq, and others; regional breakdown; and C5 franchise indication mix.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/28",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Total Revenue by medicine",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a3e78be-c8ba-4230-a311-50aaebe0d3dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.36,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Total Revenue by region",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0d17318-913a-45d0-89ab-1a1c799191b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.68,
        "y": 0.23
      },
      "kind": "chart",
      "text": "C5 franchise indications",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c62d5049-8b57-48d5-a57c-4b5f4c7304e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "All growth rates at CER. Includes Kanuma and Koselugo. Q3 2021 Total Revenue reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d8092df-7d75-45de-a4e8-6104bd9fac5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.68,
        "y": 0.72
      },
      "kind": "list",
      "text": "Neurology growing proportion of C5 franchise; Smaller proportion from ultra rare disease, PNH and aHUS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e28c93f5-38e7-44cb-a470-7ba935a5f13f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "Ultomiris +49%, neurology demand, new market access; Soliris (12%), successful conversion; Strensiq +21%, and Koselugo +81%, new patient demand",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7d51703-c9e5-43de-8ae6-2fa941d19313",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.36,
        "y": 0.72
      },
      "kind": "list",
      "text": "US +9% and EU +8%, neurology demand; ERoW +22%, neurology demand, expanded access; Emerging Markets +70%, demand growth, expanded access",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f108aa14-d426-443f-9c73-e388f983da65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Strong double-digit growth in 9M 2023 with Total Revenue +12%, momentum into year-end",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07958125-16c1-415b-8488-a2c5fd350911",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Rare Disease – 9M and Q3 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0d7da81-6240-4de7-af53-00f0dfd2ce71",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "3e5e4f6b-b167-48d7-b2be-8358607e5e9c",
      "evidence": "list/bullet: Ultomiris +49%, neurology demand, new market access; Soliris (12%), successful conversion; Strensiq +21%, and Koselugo +81%, new patient demand",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}